In a report released today, Edward White from H.C. Wainwright maintained a Buy rating on ChemoCentryx (CCXI – Research Report), with a price target of $101.00. The company’s shares closed last Tuesday at $31.51.
According to TipRanks.com, White ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -3.4% and a 32.1% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Karyopharm Therapeutics, and Aeglea Biotherapeutics.
ChemoCentryx has an analyst consensus of Strong Buy, with a price target consensus of $62.75, implying a 101.9% upside from current levels. In a report issued on February 1, Leerink Partners also reiterated a Buy rating on the stock with a $64.00 price target.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $70.21 and a one-year low of $9.53. Currently, ChemoCentryx has an average volume of 1.33M.
Based on the recent corporate insider activity of 18 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CCXI in relation to earlier this year. Last month, Joseph Feczko, a Director at CCXI bought 37,500 shares for a total of $577,750.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ChemoCentryx, Inc. is a biopharmaceutical company engages in the development and commercialization of medicines. It focuses on inflammatory disorders, autoimmune diseases, and cancer. Its drug candidates such as Avacopan and CCX140, selectively blocks a specific chemoattractant receptor, leaving the rest of the immune system intact. The company was founded by Thomas J. Schall in 1997 and is headquartered in Mountain View, CA.
Read More on CCXI:
- Texas Instruments: Very Efficient at Growing Profits
- Autolus Therapeutics (AUTL) Receives a Buy from Mizuho Securities
- BMO Capital Believes Whitecap Resources (SPGYF) Still Has Room to Grow
- Air Canada (ACDVF) Receives a Buy from BMO Capital
- Analysts Conflicted on These Healthcare Names: Boston Scientific (BSX), Cytokinetics (CYTK) and Neoleukin Therapeutics (NLTX)
